

1 **Plasma Metabolomic Profiling in Patients with Rheumatoid Arthritis Identifies Biochemical Features**
2 **Predictive of Quantitative Disease Activity**

3
4 Benjamin Hur^{1,2}, Vinod K. Gupta^{1,2}, Harvey Huang³, Kerry A. Wright⁴, Kenneth J. Warrington⁴, Veena
5 Taneja⁵, John M. Davis III^{4,*}, and Jaeyun Sung^{1,2,4,*,†}

6
7 ¹Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA

8 ²Division of Surgery Research, Department of Surgery, Mayo Clinic, Rochester, MN, USA

9 ³Mayo Clinic Medical Scientist Training Program, Mayo Clinic, Rochester, MN, USA

10 ⁴Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

11 ⁵Department of Immunology, Mayo Clinic, Rochester, MN, USA

12 *Contributed equally as co-senior authors

13 †Corresponding author: Sung.Jaeyun@mayo.edu

44 **Abstract**

45 Background: Rheumatoid arthritis (RA) is a chronic, autoimmune disorder characterized by joint
46 inflammation and pain. In patients with RA, metabolomic approaches, i.e., high-throughput profiling of small-
47 molecule metabolites, on plasma or serum has thus far enabled the discovery of biomarkers for clinical
48 subgroups, risk factors, and predictors of treatment response. Despite these recent advancements, the
49 identification of blood metabolites that reflect quantitative disease activity remains an important challenge in
50 precision medicine for RA. Herein, we use global plasma metabolomic profiling analyses to detect metabolites
51 associated with, and predictive of, quantitative disease activity in patients with RA.

52
53 Methods: Ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was
54 performed on a discovery cohort consisting of 128 plasma samples from 64 RA patients, and on a validation
55 cohort of 12 samples from 12 patients. The resulting metabolomic profiles were analyzed with two different
56 strategies to find metabolites associated with RA disease activity defined by the Disease Activity Score-28
57 using C-reactive protein (DAS28-CRP). More specifically, mixed-effects regression models were used to
58 identify metabolites differentially abundant between two disease activity groups ('lower', DAS28-CRP \leq 3.2;
59 and 'higher', DAS28-CRP $>$ 3.2); and to identify metabolites significantly associated with DAS28-CRP scores.
60 A generalized linear model (GLM) was then constructed for estimating DAS28-CRP using plasma metabolite
61 abundances. Finally, for associating metabolites with CRP (an indicator of inflammation), metabolites
62 differentially abundant between two patient groups ('low-CRP', CRP \leq 3.0 mg/L; 'high-CRP', CRP $>$ 3.0
63 mg/L) were investigated.

64
65 Results: We identified 33 metabolites differentially abundant between lower and higher disease activity groups
66 ($P < 0.05$). Additionally, we identified 51 metabolites associated with DAS28-CRP ($P < 0.05$). A GLM based
67 upon these 51 metabolites resulted in higher prediction accuracy (mean absolute error [MAE] \pm SD: 1.51 \pm 1.77)
68 compared to a GLM without feature selection (MAE \pm SD: 2.02 \pm 2.21). The predictive value of this feature set
69 was further demonstrated on a validation cohort of twelve plasma samples, wherein we observed a stronger
70 correlation between predicted vs. actual DAS28-CRP (with feature selection: Spearman's $\rho = 0.69$, 95% CI:
71 [0.18, 0.90]; without feature selection: Spearman's $\rho = 0.18$, 95% CI: [-0.44, 0.68]). Lastly, among all
72 identified metabolites, the abundances of eight were significantly associated with CRP patient groups while
73 controlling for potential confounders ($P < 0.05$).

74
75 Conclusions: We demonstrate for the first time the prediction of quantitative disease activity in RA using
76 plasma metabolomes. The metabolites identified herein provide insight into circulating pro-/anti-
77 inflammatory metabolic signatures that reflect disease activity and inflammatory status in RA patients.

78
79 **Keywords:** rheumatoid arthritis, metabolomics, plasma metabolites, DAS28-CRP, biomarker, machine-
80 learning, inflammation

88 Background

89
90 Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory disease primarily affecting the small
91 diarthrodial joints and other organ systems [1-4] that can eventually lead to bone/cartilage erosion, joint
92 deformity, loss in mobility, and organ damage [5]. Known to be associated with a variety of factors, such as
93 genetic susceptibility [6], age [7], sex [8], smoking status [9], and dietary habits [10], RA is diagnosed in
94 nearly 5 per 1000 adults worldwide, and women are 2 to 3 times more likely to develop RA than men [5]. In
95 addition, as is the case with many complex and progressive disorders, patients with RA exhibit vast
96 heterogeneity in clinical symptoms (e.g., joint inflammation, swelling, pain, stiffness) [11], and in responses
97 to methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs) [12]. Furthermore, immune
98 cells (mainly, B-cells, T-cells, and macrophages) and cytokines are known to be implicated in RA
99 pathogenesis [13]. For example, Haringman *et al.* observed that the abundance of macrophages in synovial
100 tissue was positively correlated with disease activity [14], and Chung *et al.* identified significant differences
101 in levels of multiple cytokines (e.g., IL-6, IL-11, LIF) between RA and healthy controls [15]. In this regard,
102 further understanding of the pathophysiological mechanisms that drive either progression or remission in RA
103 disease activity would be important for identifying prognostic factors and developing more effective
104 treatments [5, 16].

105 Having practical measures of disease activity is essential for determining the course of RA treatment and
106 for monitoring patient response [3]. To this end, several studies have suggested strategies to quantify (or
107 categorize) RA disease activity by using clinical and inflammatory core components, which include, but are
108 not limited to, the number of tender and swollen joints, erythrocyte sedimentation rate (ESR), serum C-reactive
109 protein (CRP) levels, and patients' pain levels [17-20]. Among these various strategies, the modified Disease
110 Activity Score that considers 28 joints (DAS28) with either ESR (DAS28-ESR) or CRP (DAS28-CRP) is
111 currently one of the most well-recognized and recommended measures in RA [20].

112 An emerging area of RA research is in using high-throughput metabolomic profiling approaches, which
113 comprehensively measure all small-molecule biochemicals in a biological specimen (e.g., plasma, serum,
114 urine, synovial fluid, etc.) to enable biomarker discovery and novel insights into the biochemical processes
115 governing disease pathophysiology [11, 21-23]. In particular, recent studies have demonstrated the promise
116 of using such metabolomic technologies on patient-derived biospecimens for classifying patients with RA
117 according to their disease activity categories [21, 24, 25], and for identifying metabolic signatures predictive
118 of treatment response [26-29]. For instance, Teitsma *et al.* used metabolomic profiling in serum samples from
119 early RA patients to identify metabolites and metabolic pathways that were significantly associated with
120 sustained, drug-free remission ($DAS28 < 2.6$) after tocilizumab- or methotrexate-based therapy [24]. Likewise,
121 Sasaki *et al.* identified 15 and 20 metabolites in plasma and urine, respectively, that were differentially
122 abundant between active RA ($DAS28-ESR \geq 3.2$) and inactive RA ($DAS28-ESR < 3.2$) [25]. These findings
123 suggest that a wider application of global metabolomic profiling—coupled with advanced analytics [30]—can
124 lead to the discovery of novel and predictive biomarkers that complement current standard laboratory tests for
125 assessing disease activity in RA.

126 To date, a global metabolomic profiling analysis to demonstrate the predictive value of blood
127 biochemicals in estimating disease activity scores for patients with RA, has remained elusive. In this study,
128 on 128 plasma metabolomic profiles from 64 RA patients, we utilize a multi-approach analysis to uncover
129 metabolites that reflect and predict RA disease activity. First, we identify metabolites that stratify patients of
130 'higher' ($DAS28-CRP \geq 3.2$) and 'lower' ($DAS28-CRP < 3.2$) disease activity groups. Next, we pinpoint

specific metabolites that significantly associate with DAS28-CRP. Interestingly, a few of the metabolites identified through these two approaches were able to differentiate between two groups of patients divided according to their C-reactive protein (CRP) levels in blood ('high-CRP', CRP > 3.0 mg/L; 'low-CRP', CRP ≤ 3.0 mg/L); these metabolites may possibly reflect metabolic perturbations affected by worsening inflammatory activity. Finally, we utilize a machine-learning technique to predict DAS28-CRP with plasma metabolite abundances. Importantly, we find that the feature selection step led to improved performance in predicting quantitative disease activity, and this translated reasonably well to a validation cohort. Taken together, our findings described herein support a key role for high-throughput metabolomic technologies in identifying blood-borne metabolic signatures of RA disease activity, and lay the groundwork for monitoring disease progression and systemic inflammation using blood samples alone.

Materials and Methods

Study Population, Subject Enrollment, Sample Collection, and Demographic Characteristics

The study population consisted of consecutive patients with RA attending the outpatient practice of the Division of Rheumatology at Mayo Clinic in Rochester, Minnesota. Eligibility required patients to be adults 18 years of age or older with a clinical diagnosis of RA by a rheumatologist, fulfilling the American College of Rheumatology/European League Against Rheumatism 2010 revised classification criteria for RA [2]. Patients were excluded if they did not comprehend English, were unable to provide written informed consent, or were members of a vulnerable population (e.g., incarcerated subjects). This led to a total of 76 patients fulfilling the eligibility criteria, who were partitioned into two groups (**Table 1**): for the discovery cohort of this study, 64 patients with available blood samples from at least two outpatient visits 6–12 months apart were included (128 total samples); for the validation cohort, 12 patients whose blood samples were available from only a single outpatient visit were included (12 total samples). Demographic and clinical data, including the numbers of tender and swollen joints, patient and evaluator global assessments, CRP (mg/L), body mass index (BMI, kg/m²), smoking status, and results for rheumatoid factor (RF, IU/mL) and anti-cyclic citrullinated peptide antibodies (anti-CCP), were collected from the electronic medical records. The patient samples (140 in total) in the study had established disease with mean age 63.54 (range: 32–86), and 69.7% (53 of 76) were female. Disease activity varied from remission to high disease activity, with a DAS28-CRP mean of 3.0 (range: 1.2–7.0). See **Additional file 1** for distribution of DAS28-CRPs corresponding to all study participants.

Table 1. Demographic characteristics of study participants.

	Discovery Cohort ^a		Validation Cohort ^b
Number of RA patients/samples	64/128		12/12
Sex of RA patients (female/male)	44/20		9/3
	Visit 1	Visit 2	-
DAS28-CRP			
Mean ± SD	3.1±1.3	3.0±1.4	2.4±1.3
Range (min–max)	1.5–7.0	1.2–6.6	1.7–5.9
Age (years)			
Mean ± SD	62.7±10.5	63.5±10.6	67.8±10.6
Range (min–max)	32–85	33–86	54–84
BMI			
Mean ± SD	30.6±5.7	31.1±6.2	27.0±4.1
Range (min–max)	22.4–45.3	22.8–47.8	19.0–33.3

N/A (n)	6	6	2
Smoking History (n)			
Current (active within 3 months)	7	5	1
Former	31	32	3
Never	25	27	7
N/A	1	0	1
CRP (mg/L)			
Mean ± SD	8.91±16.8	8.0±12.7	11.5±21.7
Range (min–max)	0.29–113	0.7–84	1.0–77.1
RF^γ (n)			
Positive	36	-	6
Negative	15	-	2
N/A	13	-	4
Anti-CCP^γ (n)			
Positive	44	-	5
Negative	13	-	1
N/A	7	-	6
Treatment			
Methotrexate use (n, %)	48 (75.0%)	49 (76.6%)	7 (58.3%)
Methotrexate dose (mg/week)			
median	20.0	20.0	22.5
IQR [Q₁, Q₃]	[15.0, 25.0]	[15.0, 25.0]	[17.5, 25.0]
Prednisone use (n, %)	29 (45.3%)	28 (43.8%)	4 (33.3%)
Prednisone dose (mg/day)			
median	5.0	5.0	5.0
IQR	[5.0, 7.0]	[5.0, 5.0]	[5.0, 5.0]
TNFi-bDMARDs^δ (n, %)	23 (35.9%)	21 (32.8%)	3 (25.0%)
non-TNFi-bDMARDs^ε (n, %)	6 (9.4%)	7 (10.9%)	1 (8.3%)
non-methotrexate csDMARDs^λ (n, %)	20 (31.2%)	27 (42.2%)	1 (8.3%)

^αTraining group. Plasma samples were obtained from patients at two different time-points; ^βTest group. Plasma samples were obtained from patients at a single time-point; ^γReported only for the first visit; ^δadalimumab, certolizumab, etanercept, and infliximab; ^εabatacept, rituximab, and tocilizumab; ^λazathioprine, hydroxychloroquine, leflunomide, and sulfasalazine; N/A, Not available; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; IQR, inter-quartile range; bDMARDs, biologic disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; an expanded table with further information on demographic and clinical characteristics is provided in **Additional file 2** and **Additional file 3**.


Metabolomic Profiling

Untargeted metabolomic profiling of plasma samples from both discovery and validation cohorts through ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was performed by Metabolon Inc. (Durham, NC, USA)'s Discovery HD4™ platform. Detailed descriptions of all methods regarding metabolomic profiling are available in **Additional file 4**.

Analysis Workflow

Figure 1 provides a summary of the analytic strategy used on the 128 plasma samples of the discovery cohort to identify associations between metabolites and RA disease activity. The analysis workflow consists of two complementary approaches: Using mixed-effects logistic regression, the first approach identifies metabolites that are differentially abundant between higher and lower disease activity groups, which were determined by DAS28-CRP scores [18-20, 31] (**Fig. 1A**); the second approach uses mixed-effects linear regression to model

183 the relationship between DAS28-CRP and metabolite abundances, allowing the detection of key biochemical
184 features that associate with quantitative disease activity (**Fig. 1B**). To test the predictive accuracy of these
185 selected features when incorporated into a generalized linear model, an additional cohort of twelve plasma
186 metabolomic profiles (from twelve RA patients obtained at single time-points) was collected as an
187 independent validation set.
188



189
190
191 **Figure 1. A multi-approach discovery strategy to identify metabolites indicative of RA disease activity.** (A) Differentially
192 abundant metabolites between higher and lower disease activity groups were identified using a mixed-effects logistic regression
193 model adjusted for patient age and sex, as well as for Patient ID to control for having multiple samples from the same patient. (B)
194 A selection scheme to identify metabolites associated with DAS28-CRP. Metabolites were selected with mixed-effects linear
195 regression. To further demonstrate their association with DAS28-CRP, these metabolites were used to construct a generalized linear
196 model for predicting DAS28-CRP. Predictive performance of the model was evaluated on the discovery cohort (using a cross-
197 validation technique) and on a validation cohort.
198

199 Pre-processing of Metabolomic Profiling Data

200 Statistical analyses on untargeted metabolomic data were performed using scaled imputed data provided by
201 Metabolon, Inc. Briefly, the raw data were normalized to account for inter-day variation, which is a result of
202 UPLC-MS/MS runs over multiple days, then the peak intensities were rescaled to set each metabolite's median
203 equal to 1. Missing values were then imputed with the minimum observed value of the metabolite across all
204 samples, finally yielding the scaled imputed data. In addition, metabolites with missing values in over 20% of
205 the entire samples were removed, resulting in 686 metabolites remaining for further analysis. R (v3.6.1), lme4
206 package (v1.1.21) [32], Python3 (v3.7.5), and sklearn (v0.22.2) were used to perform all data pre-processing
207 and statistical analyses.
208

Delineation of RA Disease Activity Groups

Following previous reports [18-20, 31], samples from RA patients were divided into two disease activity groups based upon DAS28-CRP: ‘lower’ (DAS28-CRP \leq 3.2, $n = 76$) and ‘higher’ (DAS28-CRP $>$ 3.2, $n = 52$). These pre-defined two disease activity groups were used as the nominal response variable in a mixed-effects logistic regression model to identify differentially abundant metabolites between the two groups.

Identification of Differentially Abundant Metabolites While Controlling for Confounding Factors

The following patient characteristics were examined to identify potential confounding factors in the association between plasma metabolites and disease activity (i.e., higher or lower disease activity): age, sex, BMI, smoking history, and treatment use (for methotrexate, prednisone, non-methotrexate csDMARDs, TNFi-bDMARDs, and non-TNFi-bDMARDs). Based upon the Fisher’s exact test, patient age (age \leq 60, age $>$ 60) and sex (male, female) were observed to have statistically significant associations with the two disease activity groups; the P -value for age and sex was $P = 0.01$ (odds ratio [OR] = 2.74, 95% confidence interval [CI] = 1.15–6.73) and $P = 0.02$ (OR = 0.37, 95% CI = 0.14–0.88), respectively. On the other hand, no statistically significant associations were observed between these two disease activity groups and BMI (BMI \leq 30, BMI $>$ 30; $P = 0.32$), disease duration (duration \leq 9 years, duration $>$ 9 years; $P = 0.14$), smoking history (smoked at least once, never smoked; $P = 0.36$), or treatment use (user, non-user) for methotrexate ($P = 0.83$), prednisone ($P = 0.58$), TNFi-bDMARDs, i.e., adalimumab, certolizumab, etanercept, and infliximab ($P = 0.18$), non-TNFi-bDMARDs, i.e., abatacept, rituximab, and tocilizumab ($P = 0.76$), or other non-methotrexate csDMARDs, i.e., azathioprine, hydroxychloroquine, leflunomide, and sulfasalazine ($P = 0.71$). In addition, no significant changes in treatment use were observed between the two visits; P -values of the associations between treatment use and time-point based upon McNemar’s Chi-squared test for paired nominal data were as follows: methotrexate ($P = 1$), prednisone ($P = 1$), TNFi-bDMARDs ($P = 0.75$), non-TNFi-bDMARDs ($P = 1$), and non-methotrexate csDMARDs ($P = 0.07$). Therefore, the mixed-effects logistic regression model was adjusted for age and sex as fixed effects, but not for all other aforementioned covariates. In accordance with these results, age and sex have been previously reported to be connected to RA disease activity [33-35]. Herein, patient ID was considered as a random effect in the model to account for intra-subject variance due to having repeated measurements from a single patient. By controlling for patient ID (which are unique to each patient) as a random effect, we are acknowledging the non-independence in our data, that is, sampling that has taken place from within a patient. Leveraging multiple samples from the same patient allows us to compensate for the small number of samples in higher disease activity (DAS28-CRP $>$ 3.2) in each visit (visit 1 and visit 2 having 25 and 27 samples, respectively) by maximizing the degree of freedom for the quantitative disease activity measure, and thereby to boost statistical power. Importantly, no significant difference was observed in DAS28-CRP between visit 1 and visit 2 ($P = 0.98$, Wilcoxon signed-rank test). Metabolites whose corresponding coefficients of the regression model were of P -value $<$ 0.05 were considered as differentially abundant, that is, having a statistically significant association with disease activity group.

Selection of Metabolites Associated with DAS28-CRP

Selection of metabolites associated with DAS28-CRP was performed with a mixed-effects linear regression model (DAS28-CRP as the continuous response variable), which controls for fixed effects (scaled metabolite abundances, patients’ age and sex) and for random effects (patient ID). Satterthwaite’s degrees of freedom

method supported by lmerTest (v3.1.1) [36] was applied to test for the statistical significance (P -value) of associations between metabolites and DAS28-CRP. P -values were retrieved from the corresponding regression coefficients of the predictor variables.

Evaluation of Predictive Performance of DAS28-CRP-associated Metabolites

A generalized linear model (GLM) was used to estimate DAS28-CRP scores using the aforementioned significantly associated metabolites as predictor variables. Predictive performance of the parameterized model was evaluated by two different techniques: First, a modified leave-one-out cross-validation approach was applied to the 128 samples of the training group (discovery cohort). More specifically, in each cross-validation loop, both samples from the same patient were allocated as an internal validation set, while all remaining samples (126 samples from 63 patients) were used to select metabolites significantly associated with DAS28-CRP ($P < 0.05$). These selected biochemical features were then included in a GLM for predicting DAS28-CRP scores of the remaining two samples (of the internal validation group) from their metabolite abundances. The second approach considers testing a GLM, which was composed of the DAS28-CRP-associated metabolites identified from all 128 samples of the training group, on the independent validation group of 12 plasma samples (validation cohort). For both techniques, model performance was reported using mean absolute error (MAE) and standard deviation (SD).

Identification of Metabolites Associated with Treatment Use

A marginal, mixed-effects linear regression model was used to relate metabolite abundance with treatment use. Scaled metabolite abundance, treatment use, and patient ID was set as the response variable, predictor variable (fixed effect), and random effect, respectively. Use of the following treatments was assessed individually: methotrexate, prednisone, non-methotrexate csDMARDs, TNFi-bDMARDs, and non-TNFi-bDMARDs (names of individual drugs in each treatment group are provided in the footnote of **Table 1**). P -values were retrieved from the corresponding regression coefficient of the predictor variable (i.e., use or non-use), and a significance of $P < 0.05$ was reported as statistically significant.


Identification of Differentially Abundant Metabolites Between Two CRP Groups

Metabolites that are significantly associated with disease activity groups and DAS28-CRP scores were further investigated to find those associated with patient groups delineated by CRP levels. First, all samples were divided into two groups as follows: ‘high-CRP’ (CRP > 3.0 mg/L, $n = 52$) and ‘low-CRP’ (CRP ≤ 3.0 mg/L, $n = 76$). Next, a marginal, mixed-effects linear regression model was used to define the abundance of a metabolite based upon the following fixed effects: CRP group, sex, age, smoking history, and treatment with prednisone, methotrexate, non-methotrexate csDMARDs, TNFi-bDMARDs; or non-TNFi-bDMARDs. Additionally, patient ID was treated as a random effect. Any covariates whose association with metabolite abundance was statistically significant (i.e., P -value of the corresponding regression coefficient < 0.05) were then included in an adjusted mixed model for metabolite abundance. Finally, metabolites were considered as differentially abundant between the two CRP groups if the association between metabolite abundance and CRP group was still found to be significant in the adjusted model ($P < 0.05$).

Results

Differentially Abundant Metabolites between Higher and Lower Disease Activity Groups

293 As shown in our analysis workflow (**Figure 1**), we first sought metabolites that were significantly different in
 294 abundance between two major disease activity groups. For this, we divided the 128 metabolomic profiles into
 295 two major categories (‘higher’ vs. ‘lower’) based upon the reported disease activity of the corresponding
 296 patient at the time of sample collection (**Materials and Methods**). Using a mixed-effects logistic regression
 297 model (**Materials and Methods**), we identified 33 metabolites as differentially abundant between higher (n
 298 = 52) and lower (n = 76) DAS28-CRP groups (**Fig. 2**). Most of these metabolites (31 of 33) were observed to
 299 have significantly increased abundances in lower disease activity, whereas the remaining two (glucuronate
 300 and hypoxanthine) were found to be significantly increased in higher disease activity. Notably, of the 31
 301 metabolites increased in lower disease activity, seven metabolites (3-hydroxydecanoylcarnitine, dihomol-
 302 inoleoylcarnitine (C20:2), eicosenoylcarnitine (C20:1), linoleoylcarnitine (C18:3), linoleoylcarnitine (C18:2),
 303 stearoylcarnitine (C18), palmitoylcarnitine (C16)) are a part of acylcarnitine metabolism, and represent a 3.6-
 304 fold enrichment in metabolites involved in this particular pathway ($P = 1.9 \times 10^{-3}$, hypergeometric test). It is
 305 important to note that the differences seen are relatively small in terms of fold-change, with most of the
 306 metabolites varying by 1.1–1.3 fold. Despite these subtle differences within RA patients of varying disease
 307 activities, we were still able to obtain statistically significant signal even after considering and controlling for
 308 all known potentially confounding factors (which often leads to reduction in statistical power), while adhering
 309 to our cut-offs for statistical significance ($P < 0.05$).



311
 312 **Figure 2. Plasma metabolites differentiating between higher and lower disease activity groups in RA.** A total of 2 and 31
 313 metabolites were found to be significantly increased in higher (DAS28-CRP > 3.2, n = 52) and lower (DAS28-CRP ≤ 3.2, n = 76)
 314 disease activity groups, respectively. Each point corresponds to a metabolite (686 total). Differentially abundant metabolites were
 315 found using a mixed-effects logistic regression model on the discovery cohort (128 samples), for which age and sex were adjusted.
 316 Metabolites with P -value < 0.05 (based upon the corresponding coefficient of the regression model) were considered as significantly

317 different between groups. *P*-values and fold-changes for all metabolites are listed in **Additional file 5**. Metabolites in bold have
318 been previously described in the literature for their associations with RA.

319
320 N2-acetyl,N6-methyllysine ($|\log_2(\text{FC})| = 1.11$, $P = 1.26 \times 10^{-2}$) and trigonelline (N'-methylnicotinate)
321 ($|\log_2(\text{FC})| = 0.74$, $P = 2.09 \times 10^{-2}$), which were both found to have increased abundance in lower disease
322 activity, were the top two metabolites having the largest fold-changes between the two groups. Although the
323 direct relevance of N2-acetyl,N6-methyllysine to RA is currently not well understood, N2-acetyl,N6-
324 methyllysine is part of the lysine metabolism pathway, which has been reported to be associated with RA in
325 the following studies: i) according to Teitsma *et al.*, serum metabolites associated with lysine degradation
326 were observed to have a higher concentration in early RA patients who achieved sustained drug-free remission
327 (after Tocilizumab- or Methotrexate-based treatment) compared to those who never achieved a drug-free
328 status [24]; and ii) Yang *et al.* reported that metabolic products of lysine degradation (carnitine and piperolic
329 acid) were significantly increased in RA patients than in normal subjects [37].

330 In regard to trigonelline, which is a product of niacin (vitamin B3) metabolism, this alkaloid has been
331 suggested to have therapeutic potential for diabetes and central nervous system disease [38], and also reported
332 to demonstrate anti-inflammatory properties in mice [39]. In accordance with our results showing decreased
333 abundance of trigonelline in higher disease activity, trigonelline could be of interest in future studies on
334 inflammatory responses in RA.


335 Biliverdin ($|\log_2(\text{FC})| = 0.48$, $P = 1.38 \times 10^{-2}$) and bilirubin (E,E) ($|\log_2(\text{FC})| = 0.43$, $P = 1.18 \times 10^{-2}$),
336 which are known metabolic products of the heme catabolic pathway, were also observed to have significantly
337 increased abundances in lower disease activity. In particular, biliverdin has been shown to: i) inhibit the
338 activation of pro-inflammatory transcription factors, including NFkB both *in vitro* and *in vivo* [40-44]; ii)
339 inhibit the proliferation of primary T cells stimulated with anti-CD3 and anti-CD28 monoclonal antibodies by
340 inhibiting NFAT/NF-kB activation in a mouse model of heart transplantation [45]; and iii) improve corneal
341 inflammation mediated by heme-oxygenase 2 (HO-2) deficiency in a transgenic mouse model [41]. Moreover,
342 bilirubin, which is derived from the reduction of biliverdin by biliverdin reductase, has been reported as a
343 potential biomarker for RA in line with our findings. For example, Peng *et al.* observed a decreased
344 concentration of serum bilirubin in RA patients compared to healthy controls, as well as in RA patients with
345 worsening disease activity [46]. Additionally, Fischman *et al.* found that total bilirubin levels are inversely
346 related to RA disease activity even after adjusting for multiple confounders (e.g., age, sex, race), and discussed
347 the possibility of bilirubin (a known anti-oxidant) having a physiological anti-inflammatory effect [47]. This
348 point is further elaborated upon by Jangi *et al* [48], who have described in detail the immunosuppressive
349 properties of unconjugated bilirubin in RA and other inflammatory disorders. The full list of differentially
350 abundant metabolites and their associated pathways are shown in **Additional file 5**.

351 **Metabolic Feature Selection Improves DAS28-CRP Prediction Accuracy**

352 Having uncovered metabolites demonstrating altered abundance between two major disease activity groups,
353 we next asked whether quantitative disease activity can be predicted with plasma metabolomes. As untargeted
354 metabolomic profiling can yield a considerable amount of noise and random fluctuations in observed signals
355 [49], it is necessary to first select informative metabolic features that reliably capture relevant aspects of the
356 phenotype of interest [50]. For this, we used mixed-effects linear regression models to select metabolites
357 significantly associated with DAS28-CRP. Afterwards, the abundances of the selected metabolic features were
358 incorporated into a generalized linear model (GLM) to predict DAS28-CRP. For comparison purposes, a GLM
359 was constructed without metabolic feature selection, and thereby taking into consideration all features of a
360

361 metabolomic profile. Details regarding GLM construction and performance evaluation are provided in
362 **Materials and Methods**.

363 When applying a modified leave-one-out cross-validation technique to the training group samples ($n =$
364 128), we found that the GLM incorporating metabolites that were significantly associated with DAS28-CRP
365 outperformed the model without feature selection (i.e., using all metabolites). As shown in **Figure 3**, the
366 distribution of absolute errors between the observed and predicted DAS28-CRP scores was smaller (with
367 respect to the cumulative area under the error curve) for the GLM with feature selection than that without
368 feature selection. To this point, the prediction MAE (\pm SD) of the GLM with and without feature selection was
369 1.51 (\pm 1.89) and 2.02 (\pm 2.52), respectively.



370 **Figure 3. Evaluation of DAS28-CRP predictive performance in cross-validation.** A modified leave-one-out cross-validation
371 approach was used on the samples of the training group (128 samples) to test the performance of a generalized linear model (GLM)
372 in predicting DAS28-CRP scores from metabolite abundances. Distributions of absolute errors from models with and without a
373 feature selection scheme were compared to identify the more robust model. The GLM with the feature selection scheme performed
374 better (MAE \pm SD: 1.51 \pm 1.89) than the model without feature selection (MAE \pm SD: 2.02 \pm 2.52).
375
376

377 Having confirmed that feature selection can lead to a more accurate prediction model in cross-validation,
378 we applied the same scheme to all metabolome samples of the discovery cohort to obtain a final set of
379 metabolites associated with DAS28-CRP ($P < 0.05$). After adjusting for potential confounding factors
380 (**Materials and Methods**), this resulted in a collection of 51 plasma metabolites (**Table 2**). These metabolites
381 were used to construct a final GLM, whose predictive accuracy was tested on an independent validation cohort
382 ($n = 12$) of plasma metabolomic profiles from twelve RA patients (importantly, this additional cohort was not
383 drawn from the same population distribution from which the features were derived). On this previously unseen
384 cohort, the GLM constructed with only the 51 selected metabolites performed considerably better than the
385 model without the feature selection scheme by over two-fold (**Fig. 4A**); the prediction MAE of the GLM with
386 and without feature selection was 0.97 (\pm 0.47) and 2.01 (\pm 2.18), respectively. Likewise, when the actual and
387 predicted DAS28-CRPs were plotted together for both GLMs (**Fig. 4B**), we found that the model with the
388 selection scheme performed more favorably. More specifically, a stronger correlation between the actual and
389 predicted disease activity scores was observed in the model with feature selection (Spearman's $\rho = 0.69$, $P =$
390 1.40×10^{-2} , 95% CI: [0.18, 0.90]) compared to the model without (Spearman's $\rho = 0.18$, $P = 5.72 \times 10^{-2}$, 95%
391 CI: [-0.44, 0.68]).
392


393

Table 2. Plasma metabolites significantly associated with DAS28-CRP.

Metabolite Name	Super-Pathway ^α	Sub-Pathway ^α	HMDB ID ^β	Regression Coefficient ^γ	P-value ^δ
3-hydroxystearate	Lipid	Fatty Acid, Monohydroxy	N/A	0.418	0.002
Phenol sulfate	Amino Acid	Tyrosine Metabolism	HMDB60015	-0.265	0.003
Trimethylamine N-oxide	Lipid	Phospholipid Metabolism	HMDB00925	0.485	0.004
Bilirubin (E,E)	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism	N/A	-0.612	0.007
Serine	Amino Acid	Glycine, Serine and Threonine Metabolism	HMDB00187	-1.594	0.010
Dimethylguanidino valeric acid (DMGV)	Amino Acid	Urea cycle; Arginine and Proline Metabolism	N/A	0.325	0.011
N-acetyltryptophan	Amino Acid	Tryptophan Metabolism	HMDB13713	-0.918	0.012
Glycoursodeoxycholate	Lipid	Secondary Bile Acid Metabolism	HMDB00708	0.051	0.012
N-acetylneuraminate	Carbohydrate	Aminosugar Metabolism	HMDB00230	0.470	0.013
Dihomo-linoleoylcarnitine (C20:2)	Lipid	Fatty Acid Metabolism (Acyl Carnitine, Polyunsaturated)	N/A	-0.745	0.013
N-acetyltyrosine	Amino Acid	Tyrosine Metabolism	HMDB00866	-0.713	0.014
Branched chain 14:0 dicarboxylic acid	Lipid	Fatty Acid, Dicarboxylate	N/A	-0.201	0.014
1-carboxyethylvaline	Amino Acid	Leucine, Isoleucine and Valine Metabolism	N/A	0.408	0.015
(14 or 15)-methylpalmitate (a17:0 or i17:0)	Lipid	Fatty Acid, Branched	N/A	0.227	0.017
Isoursodeoxycholate	Lipid	Secondary Bile Acid Metabolism	HMDB00686	0.059	0.018
Glucuronate	Carbohydrate	Aminosugar Metabolism	HMDB00127	0.396	0.019
Glucose	Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism	HMDB00122	1.107	0.019
Linoleoylcarnitine (C18:3)	Lipid	Fatty Acid Metabolism (Acyl Carnitine, Polyunsaturated)	N/A	-0.534	0.020
1-methylhistidine	Amino Acid	Histidine Metabolism	HMDB00001	0.580	0.020
Trigonelline (N'-methylnicotinate)	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism	HMDB00875	-0.227	0.020
Palmitoyl ethanolamide	Lipid	Endocannabinoid	HMDB02100	0.067	0.020
Hypoxanthine	Nucleotide	Purine Metabolism, (Hypo)Xanthine/Inosine containing	HMDB00157	0.482	0.022
Biliverdin	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism	HMDB01008	-0.436	0.022
Linoleoylcarnitine (C18:2)	Lipid	Fatty Acid Metabolism (Acyl Carnitine, Polyunsaturated)	HMDB06469	-0.814	0.023
3-methylhistidine	Amino Acid	Histidine Metabolism	HMDB00479	0.140	0.025
N-acetylgarginine	Amino Acid	Urea cycle; Arginine and Proline Metabolism	HMDB04620	-0.755	0.026
4-guanidinobutanoate	Amino Acid	Guanidino and Acetamido Metabolism	HMDB03464	0.347	0.026
1-carboxyethylisoleucine	Amino Acid	Leucine, Isoleucine and Valine Metabolism	N/A	0.307	0.026
Cysteinylglycine disulfide	Amino Acid	Glutathione Metabolism	HMDB00709	1.562	0.027
Guanidinoacetate	Amino Acid	Creatine Metabolism	HMDB00128	-1.125	0.027
N2-acetyl,N6-Methyllysine	Amino Acid	Lysine Metabolism	N/A	-0.213	0.028
Lysine	Amino Acid	Lysine Metabolism	HMDB00182	-1.395	0.031
1,6-anhydroglucose	Xenobiotics	Food Component/Plant	HMDB00640	0.097	0.032
Pyrraline	Xenobiotics	Food Component/Plant	HMDB33143	0.190	0.032

Mannose	Carbohydrate	Fructose, Mannose and Galactose Metabolism	HMDB00169	0.633	0.032
Ectoine	Xenobiotics	Chemical	N/A	0.123	0.036
6-bromotryptophan	Amino Acid	Tryptophan Metabolism	N/A	-0.758	0.037
1-linoleoyl-GPA (18:2)	Lipid	Lysophospholipid	HMDB07856	-0.371	0.039
Eicosenoylcarnitine (C20:1)	Lipid	Fatty Acid Metabolism (Acyl Carnitine, Monounsaturated)	N/A	-0.557	0.039
Erucate (22:1n9)	Lipid	Long Chain Monounsaturated Fatty Acid	HMDB02068	0.346	0.040
Bilirubin	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism	HMDB00054	-0.432	0.042
Stearoyl ethanolamide	Lipid	Endocannabinoid	HMDB13078	0.070	0.043
3-phenylpropionate (hydrocinnamate)	Xenobiotics	Benzoate Metabolism	HMDB00764	-0.178	0.043
beta-hydroxyisovalerate	Amino Acid	Leucine, Isoleucine and Valine Metabolism	HMDB00754	0.723	0.045
Myo-inositol	Lipid	Inositol Metabolism	HMDB00211	0.944	0.045
Gulonate	Cofactors and Vitamins	Ascorbate and Aldarate Metabolism	HMDB03290	0.575	0.047
Gluconate	Xenobiotics	Food Component/Plant	HMDB00625	0.539	0.047
Tryptophan	Amino Acid	Tryptophan Metabolism	HMDB00929	-1.139	0.048
1-carboxyethylleucine	Amino Acid	Leucine, Isoleucine and Valine Metabolism	N/A	0.350	0.048
alpha-ketobutyrate	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism	HMDB00005	0.268	0.049
Lanthionine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism	N/A	-0.229	0.049

394 ^aSuper-pathways and sub-pathways were defined by Metabolon's Discovery HD4™ platform; ^bMetabolite IDs provided by the
 395 Human Metabolome Database (HMDB); ^cCoefficients of the predictor variables (metabolites) in the mixed-effects linear regression
 396 model from discovery cohort (n = 128). Sign and magnitude of the coefficient indicate direction and strength of the correlation
 397 (between the metabolite and DAS28-CRP), respectively; ^dP-values were retrieved from the corresponding regression coefficients;
 398 N/A, not available.
 399



400
 401 **Figure 4. GLM with feature selection provides improved DAS28-CRP prediction accuracy in an independent validation**
 402 **group (12 samples).** (A) Performance of GLMs in predicting quantitative disease activity were evaluated on samples of an
 403 independent validation group. Distributions of absolute errors from models with and without a feature selection scheme were
 404 compared to identify the more robust model. (B) Selection of metabolic features prior to model training resulted in higher predictive
 405 performance, as evidenced by the stronger correlation between observed and predicted DAS28-CRPs. Three samples predicted to
 406 have negative DAS28-CRP values are omitted from the scatter-plot. Dashed violet line indicates 'y = x', i.e., an exact match between

the observed and predicted values. 95% confidence interval for ρ with feature selection: [0.18, 0.90]; without feature selection: [0.44, 0.68].

Commonly Identified Metabolites from Two Different Analytic Approaches

To summarize the findings above, we found that, from the 686 total detectable metabolites in a metabolomic profile, 33 (4.8%) were differentially abundant between higher and lower disease activity; and 51 (7.4%) were significantly associated with DAS28-CRP (Fig. 5). These separate findings amounted to a total of 67 unique metabolites, among which 40 were found to have no association with the use of prednisone, methotrexate, other non-methotrexate csDMARDs, TNFi-bDMARDs, or non-TNFi-bDMARDs (Materials and Methods). Notably, eight metabolites (6-bromotryptophan, bilirubin (E,E), biliverdin, glucuronate, N-acetyltryptophan, N-acetyltyrosine, serine, and trigonelline) were not only consistently detected across both analytic approaches, but also found to have no association with any treatment use; these results strongly suggest key metabolic pathways and modules potentially contributing to, or serving as indicators of, RA pathogenesis independent of confounding treatment effects. Consistent with this idea, additional studies into the metabolites found in this study (the majority of which have yet to be linked to RA) may be able to provide new insight into the perturbed physiological metabolic processes—which are then in turn reflected in blood—underlying disease progression in RA.





Figure 5. Venn diagram of all plasma metabolites identified through the multi-approach discovery strategy. A total of 67 unique metabolites were identified, among which 40 were found to have no association with the use of treatment. Notably, eight metabolites (6-bromotryptophan, bilirubin (E,E), biliverdin, glucuronate, N-acetyltryptophan, N-acetyltyrosine, serine, and trigonelline) in bold were not only consistently detected across both analytic approaches, but also found to have no association with any treatment use. Colored circles indicate metabolites whose abundances associate with treatment use. Metabolites with red triangles were found to have increasing abundances with worsening disease activity, whereas metabolites with blue triangles were found to have decreasing abundances with worsening disease activity.

Metabolites Associated with CRP Patient Groups

435 Elevated levels of C-reactive protein (CRP) in the blood is well known to often indicate increased
436 inflammatory conditions, which may be caused by a wide variety of acute (e.g., infections) and chronic
437 disorders (e.g., rheumatoid arthritis, inflammatory bowel disease). In RA patients, CRP levels have been
438 observed to increase after acute mental stress tasks [51], and also to be linked to risk of cardiovascular disease
439 [52]. Furthermore, several serum metabolites were found to reflect inflammatory activity in patients with early
440 arthritis [53].

441 We further investigated the aforementioned 67 plasma metabolites to see whether any were differentially
442 abundant between two CRP patient groups, i.e., ‘high-CRP’ (CRP > 3.0 mg/L, n = 52) and ‘low-CRP’ (CRP
443 ≤ 3.0 mg/L, n = 76) (**Materials and Methods**). While controlling for potential confounding variables, we
444 identified eight total metabolites that were significantly associated with CRP patient group. More specifically,
445 the abundances of mannose, beta-hydroxyisovalerate, (14 or 15)-methylpalmitate (a17:0 or i17:0), erucate
446 (22:1n9), 10-undecenoate (11:1n1), N-acetylcitrulline were higher in high-CRP, while those of serine and
447 linoleoylcarnitine (C18:3) were lower in high-CRP (**Fig. 6**). Application of these plasma metabolites, which
448 were found to be connected to both RA disease activity and circulating CRP levels, may lead to the
449 development of new clinical laboratory tests to further enable precision medicine for RA patients.
450



451 **Figure 6. Metabolites differentially abundant between two CRP patient groups.** Among the 67 total metabolites identified
452 through our multi-approach analysis on the discovery cohort (n = 128), eight metabolites were identified to have significant
453 associations with CRP group while controlling for confounding variables (regression coefficient for CRP, $P < 0.05$) (A) Metabolites
454 with higher abundances in the high-CRP group: mannose, beta-hydroxyisovalerate, (14 or 15)-methylpalmitate (a17:0 or i17:0),
455 erucate (22:1n9), 10-undecenoate (11:1n1), and N-acetylcitrulline. (B) Metabolites with higher abundances in the low-CRP group:
456 serine and linoleoylcarnitine (C18:3).
457
458

459 Plasma metabolites associate with clinical improvement in RA

460 Based upon the European League Against Rheumatism (EULAR) response criteria for DAS28-CRP [54], we
461 found that sixteen of the 64 patients in the discovery cohort showed moderate or good improvement in disease
462 activity from visit 1 to visit 2, while the remaining 48 patients did not show clinical improvement at the time
463 of their second visit. This discovery provided an entry point for the following analysis: For each of these two
464 patient groups, i.e., ‘Improved’ (n = 16) and ‘Non-improved’ (n = 48) patients, we aimed to identify
465 metabolites whose abundances significantly changed from visit 1 to visit 2, while controlling for the same
466 confounding factors (mixed-effects regression model, $P < 0.05$). As a result, we identified eleven metabolites
467 whose abundances significantly changed in the Improved patient group (**Additional file 6**), while nineteen
468 metabolites showed significant changes in the Non-improved patient group (**Additional file 7**). The following
469 three metabolites, which were discovered in our previous analyses on the 128 plasma metabolome samples of
470 the discovery cohort, were detected once again: erucate (22:1n9), a metabolite identified to be associated with
471 both DAS28-CRP and CRP patient group, was identified to be significantly different between visit 1 and visit
472 2 in patients who did not show clinical improvement (Non-improved); 3-amino-2-piperidone, a metabolite
473 identified to be differentially abundant between higher and lower disease activity in our study, was identified
474 to be significantly different between visit 1 and visit 2 in patients who showed clinical improvement
475 (Improved); and gamma-glutamylmethionine, a metabolite identified to be differentially abundant between
476 higher and lower disease activity, was identified to be significantly different between visit 1 and visit 2 in the
477 Non-improved group. These results allow us to expand our future direction to investigate metabolites
478 associated with clinical improvement in patients with RA.

479 **Discussion**

480
481
482 Dysfunctions in cellular and tissue metabolism are involved in a broad range of autoimmune disorders [55-
483 58], including RA [59-61]. These metabolic implications highlight the importance of investigating which
484 biochemical functions and metabolic states are altered during the onset and progression of disease. To this
485 end, metabolomics platforms (and the accompanying wealth of data) can present unique opportunities for
486 discovering novel disease ‘molecular signatures’ [62], which can be interpreted through the lens of annotated
487 biochemical relationships. Moreover, high-throughput profiling can enable the identification of circulating
488 pro-inflammatory (disease-triggering) and anti-inflammatory (disease-protective) metabolites in RA, as
489 elaborated upon by Coras *et al.* [63]; such discoveries may facilitate the design of either dietary or gut
490 microbiome-based intervention strategies to improve wellness or alter the course of disease for RA patients. In
491 this study, by performing a global metabolomic profiling analysis on 128 plasma samples obtained from 64
492 patients with RA, we identified biochemical signatures associated with, and predictive of, disease activity.
493 Mainly, through a combination of statistical approaches for metabolic signature discovery, we identified
494 several metabolites that: i) differ significantly between lower and higher disease activity groups; and ii)
495 significantly associate with DAS28-CRP. Of note, our study is the first to leverage biochemical features from
496 a plasma metabolomic profile to predict quantitative disease activity.

497 Interestingly, we identified eight metabolites (6-bromotryptophan, bilirubin (E,E), biliverdin, glucuronate,
498 N-acetyltryptophan, N-acetyltyrosine, serine, and trigonelline) that were commonly found across different
499 statistical approaches, possibly capturing representative metabolite signals of RA progression. We discussed
500 above the reported roles of bilirubin and biliverdin in RA. Moreover, these two metabolites were previously
501 reported for their cytoprotective and anti-inflammatory effects [64-68], and even suggested as an “RA
502 protective factor” by Fischman *et al.* [47]. Interestingly, high concentrations of bilirubin and biliverdin were
503 reported in other inflammatory disorders, such as atherosclerotic diseases [69] and autoimmune encephalitis

[67]. In regards to the other six metabolites, clear and definitive connections with RA have not yet been established. However, if our results on bilirubin and biliverdin were to serve as benchmarks for reliably identifying plasma metabolites important to RA disease activity, then these remaining metabolites may be deemed as leading candidates for future investigations.

Glucuronate was found to show elevated abundance in higher disease activity than in lower disease activity. This glucose-derivative is involved in the detoxification of xenobiotics via glucuronidation in the mammalian liver. Interestingly, this process can be reversed by gut bacteria harboring β -D-glucuronidases [70], and thereby releasing (potentially toxic) exogenous compounds into the gut lumen and subsequently into circulation [71, 72]. In that respect, examining a possible role involving dysbiosis in the gut microbiota—combined with metabolomic approaches to infer relationships between gut microbes and blood metabolites in RA, as shown by Chen *et al.* [73]—may help elucidate a microbial-based mechanism explaining the observed alterations in plasma glucuronate.

Serine was seen to decrease with worsening disease activity. In line with our results, albeit in an RA mouse model with collagen-induced arthritis (CIA), plasma levels of serine and other free amino acids were found to have significantly decreased in the CIA group compared to control mice [74]. In another study wherein synovial fluid of RA patients were examined for citrullinated proteins (which is widely known to result in a rise in anti-citrullinated protein antibodies in RA), Tilvawala *et al.* found increased citrullination in a wide array of serine protease inhibitors (Serpins) and serine proteases [75]; in the same study, the investigators demonstrated *in vitro* that citrullinating serine protease inhibitors nearly abolishes their inhibitory activity towards their target proteases. Although we have yet to uncover whether a decrease in plasma serine levels (with worsening disease activity) is linked to citrullination of serine proteases in synovial fluid, we speculate that changes in serine may reflect dysregulated protein degradation during systemic inflammatory activity and joint destruction in RA.

We note a few limitations of this study: First, we acknowledge that our study includes a relatively small number of samples within each disease activity group of the discovery cohort and the validation cohort. Nevertheless, we were able to detect statistically significant metabolites in all analytical strategies, demonstrating that our data provides reasonably sufficient statistical power. Certainly, a much larger cohort would have been ideal; however, this is a small pilot study on our stored plasma samples, and obtaining an additional cohort is outside of its scope. Encouragingly, despite the low sample size of the validation cohort, we were able to successfully show that feature selection is a necessary step in the model-training process, and we expect this finding to translate well to larger cohorts in our future studies. Nevertheless, in order to more meticulously examine the role of blood metabolites in RA, future investigations will warrant a higher number of samples and more detailed subject characteristics. Second, to define RA disease activity, we solely used the DAS28-CRP scoring system, which is dependent upon acute-phase responses that may not accurately reflect patients who have an inflammation-free state [24]. Our future plans include performing our analytical pipeline with other RA disease activity metrics (e.g., clinical disease activity index (CDAI), simple disease activity index (SDAI)) to test the robustness of our findings. Third, all of our multivariate analyses followed adjustment for patient age and sex only. Other potential confounders that may affect the concentration of blood metabolites, such as diet, exercise habits, lifestyle factors, time of the day of sample collection, and gut microbiome, were not considered as predictor variables in our analyses. Fourth, comorbidity can certainly be a significant confounding factor. Alternatively, comorbidities could theoretically be contributors or mediators to inflammatory disease activity in patients with RA. At this stage, it would have been premature to adjust statistically for the effects of particular comorbidities or for the presence of multi-morbidity (i.e., multiple chronic conditions) before carefully investigating for their potential interaction with plasma metabolites and

548 RA disease activity. This may lead to ‘over-adjustment’ and falsely concluding that certain metabolites are
549 not significant when they may, in fact, be very important. Future studies will be necessary to explore potential
550 interactions between comorbidities, RA disease activity, and plasma metabolite levels in RA. Last, despite the
551 similarities in our findings with previous investigations (as noted above), many of our results are reported for
552 the first time and remain to be validated by others. Possible causes of discrepancies with the work of others
553 include the comparatively small number of samples in this pilot study; technical and biological sources of
554 random noise; the uniqueness of our recruited patient cohort; variabilities in detection protocols and
555 instrument sensitivity; and use of alternate statistical techniques and potential over-fitting. Future efforts, by
556 us and others, are likely to elucidate truly robust signal and collectively strengthen the confidence in our novel
557 findings.

558 Despite the aforementioned limitations, our study establishes the far-reaching utility of using cutting-edge
559 technological and analytical approaches for plasma metabolomic profiling and justifies analogous
560 investigations at larger scales. The identified metabolites could be a reflection of the perturbed metabolic
561 processes concurrent with worsening disease activity, and our findings will inspire future studies into how
562 inflammation and pain in RA are coupled to physiological metabolism. Moreover, our identified sets of
563 signature metabolites offer a promising glimpse into biomolecular marker panels for diagnosing disease
564 activity of RA patients solely through blood (thereby complementing current diagnostic approaches), with the
565 overall aim to make such assessments faster, cheaper, and less invasive. In turn, studies such as ours are
566 expected to contribute towards fully realizing the potential of virtual and digital healthcare by foregoing the
567 need for patients to physically arrive at the clinic to meet their primary care provider in person.

568 As the gut microbiome has been recognized to be implicated in RA [73, 76-78]—possibly through
569 complex mechanisms underlying microbe-microbe and host-microbe biochemical cross-talk [79]—integrated
570 profiling of both stool metagenome and blood metabolome would provide an in-depth, comprehensive view
571 of functional dysbiosis during RA onset and progression. Interestingly, a recent study showed that blood
572 metabolites can be predictive of gut microbiome alpha-diversity [80]. Such investigations into integrating
573 across multiple data types of the same phenotype can help to amplify the primary biological signal of interest
574 relative to noise, as well as provide actionable insights. In conclusion, the results reported herein are poised
575 to eventually improve disease management and outcomes of patients with RA and other rheumatic diseases,
576 as well as to provide novel means of monitoring health and wellness [81].

577 **List of Abbreviations**

578 RA: Rheumatoid arthritis; DMARDs: Disease-modifying anti-rheumatic drugs; bDMARDs: Biologic disease-
579 modifying anti-rheumatic drugs; csDMARDs: Conventional synthetic disease-modifying anti-rheumatic
580 drugs; UPLC-MS/MS: Ultra-high performance liquid chromatography-tandem mass spectrometry; DAS28-
581 CRP: Disease Activity Score-28 using C-reactive protein; BMI: Body mass index; GLM: Generalized linear
582 model; MAE: Mean absolute error; SD: Standard deviation; ESR: Erythrocyte sedimentation rate; CRP: C-
583 reactive protein; Anti-CCP: anti-cyclic citrullinated peptide antibodies; HMDB: Human metabolome database;
584 CIA: Collagen-induced arthritis; CDAI: Clinical disease activity index; SDAI: Simple disease activity index.

585 **Supplementary Information**

586
587 Additional file 1: Supplementary Figure 1, Histogram of DAS28-CRPs corresponding to the 128 total samples
588 of the discovery cohort.

589
590 Additional file 2: Supplementary Table 1, Subject characteristics of 64 patients (128 samples) from the
591 discovery cohort.

592 Additional file 3: Supplementary Table 2, Subject characteristics of 12 patients (12 samples) from the
593 validation cohort.

594 Additional file 4: Supplementary Information on detailed methods regarding metabolomic profiling
595 (Metabolon).

596 Additional file 5: Supplementary Table 3, Differentially abundant metabolites between lower (DAS28-CRP
597 ≤ 3.2) and higher (DAS28-CRP > 3.2) disease activity groups.

598 Additional file 6: Supplementary Table 4, Metabolites displaying significant changes in abundances in patients
599 with clinical improvement.

600 Additional file 7: Supplementary Table 5, Metabolites displaying significant changes in abundances in patients
601 without clinical improvement.

602

603 **Declarations**

604

605 *Ethics approval and consent to participate*

606 This study was approved by the Mayo Clinic Institutional Review Board (no. 14-000616 and no. 14-000680)
607 in accordance with the Declaration of Helsinki. All methods and procedures were performed in accordance
608 with Mayo Clinic Institutional Review Board guidelines and regulations.

609

610 *Consent for publication*

611 All patients provided written informed consent.

612

613 *Availability of data and materials*

614 All raw metabolomic datasets, as well as source codes used to reproduce all results in this study, are available
615 at https://github.com/jaeyunsung/RA_plasma_metabolomics_2020.

616

617 *Competing interests*

618 The authors declare no competing interests.

619

620 *Funding*

621 This work was supported in part by the Mayo Clinic Center for Individualized Medicine (to B.H., V.K.G., and
622 J.S.), and Mark E. and Mary A. Davis to Mayo Clinic Center for Individualized Medicine (J.M.D. and J.S.).

623

624 *Authors' contributions*

625 B.H., J.M.D., and J.S. conceived the problem and designed all analytical methodologies. B.H. performed all
626 computational analyses. All authors analyzed the data. B.H., J.M.D., and J.S. wrote the manuscript, with
627 editorial contributions from other authors. J.M.D. is the principal investigator of the Mayo Clinic
628 Rheumatology Biobank, from which blood samples were collected from patients with rheumatoid arthritis.
629 All authors reviewed and approved the final manuscript.

630

631 *Acknowledgements*

632 First and foremost, we thank our dear patients who volunteered for this study. We also thank the Mayo Clinic
633 Division of Rheumatology study coordinators (Jennifer Sletten and Kathleen McCarthy-Fruin) for their help
634 in making this work possible.

635

References

1. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: **Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies**. *Bone research* 2018, **6**(1):1-14.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD: **2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative**. *Arthritis & rheumatism* 2010, **62**(9):2569-2581.
3. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V *et al*: **Rheumatoid arthritis**. *Nature Reviews Disease Primers* 2018, **4**(1):18001.
4. Firestein GS: **Evolving concepts of rheumatoid arthritis**. *Nature* 2003, **423**(6937):356-361.
5. Aletaha D, Smolen JS: **Diagnosis and management of rheumatoid arthritis: a review**. *Jama* 2018, **320**(13):1360-1372.
6. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ: **Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins**. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 2000, **43**(1):30-37.
7. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis III JM, Hunder GG, Therneau TM, Gabriel SE: **The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases**. *Arthritis & Rheumatism* 2011, **63**(3):633-639.
8. Ngo ST, Steyn FJ, McCombe PA: **Gender differences in autoimmune disease**. *Frontiers in neuroendocrinology* 2014, **35**(3):347-369.
9. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai S: **Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies**. *Annals of the rheumatic diseases* 2010, **69**(01):70-81.
10. Khanna S, Jaiswal KS, Gupta B: **Managing rheumatoid arthritis with dietary interventions**. *Frontiers in nutrition* 2017, **4**:52.
11. Julià A, Alonso A, Marsal S: **Metabolomics in rheumatic diseases**. *International Journal of Clinical Rheumatology* 2014, **9**(4):353.
12. Aletaha D, Smolen J: **The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses**. *Rheumatology* 2002, **41**(12):1367-1374.
13. Yap H-Y, Tee SZ-Y, Wong MM-T, Chow S-K, Peh S-C, Teow S-Y: **Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development**. *Cells* 2018, **7**(10):161.
14. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak P: **Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis**. *Annals of the rheumatic diseases* 2005, **64**(6):834-838.
15. Chung S-J, Kwon Y-J, Park M-C, Park Y-B, Lee S-K: **The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients**. *Yonsei medical journal* 2011, **52**(1):113-120.
16. Arts EE, Fransen J, Den Broeder AA, van Riel PL, Popa CD: **Low disease activity (DAS28 ≤ 3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study**. *Annals of the Rheumatic Diseases* 2017, **76**(10):1693-1699.
17. Van Gestel A, Prevoo M, Van't Hof M, Van Rijswijk M, Van de Putte L, Van Riel P: **Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria**. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 1996, **39**(1):34-40.
18. Prevoo M, Van't Hof MA, Kuper H, Van Leeuwen M, Van De Putte L, Van Riel P: **Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective**

- 685 **longitudinal study of patients with rheumatoid arthritis.** *Arthritis & Rheumatism: Official Journal*
686 *of the American College of Rheumatology* 1995, **38**(1):44-48.
- 687 19. Fransen J, Van Riel P: **The Disease Activity Score and the EULAR response criteria.** *Clinical and*
688 *experimental rheumatology* 2005, **23**(5):S93.
- 689 20. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'dell JR, Kazi S:
690 **Rheumatoid arthritis disease activity measures: American College of Rheumatology**
691 **recommendations for use in clinical practice.** *Arthritis care & research* 2012, **64**(5):640-647.
- 692 21. Li J, Che N, Xu L, Zhang Q, Wang Q, Tan W, Zhang M: **LC-MS-based serum metabolomics reveals**
693 **a distinctive signature in patients with rheumatoid arthritis.** *Clinical rheumatology* 2018,
694 **37**(6):1493-1502.
- 695 22. Patti GJ, Yanes O, Siuzdak G: **Metabolomics: the apogee of the omics trilogy.** *Nature reviews*
696 *Molecular cell biology* 2012, **13**(4):263-269.
- 697 23. Clish CB: **Metabolomics: an emerging but powerful tool for precision medicine.** *Molecular Case*
698 *Studies* 2015, **1**(1):a000588.
- 699 24. Teitsma XM, Yang W, Jacobs JW, Pethö-Schramm A, Borm ME, Harms AC, Hankemeier T, van Laar
700 JM, Bijlsma JW, Lafeber FP: **Baseline metabolic profiles of early rheumatoid arthritis patients**
701 **achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate,**
702 **or the combination: insights from systems biology.** *Arthritis research & therapy* 2018, **20**(1):230.
- 703 25. Sasaki C, Hiraishi T, Oku T, Okuma K, Suzumura K, Hashimoto M, Ito H, Aramori I, Hirayama Y:
704 **Metabolomic approach to the exploration of biomarkers associated with disease activity in**
705 **rheumatoid arthritis.** *PloS one* 2019, **14**(7).
- 706 26. Hambardzumyan K, Bolce RJ, Wallman JK, Van Vollenhoven RF, Saevarsdottir S: **Serum biomarkers**
707 **for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: Results**
708 **from the SWEFOT trial.** *The Journal of rheumatology* 2019, **46**(6):555-563.
- 709 27. Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, Ando T, Nakayama Y, Okuzono Y,
710 Takiguchi M: **Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of**
711 **molecular remission.** *Nature communications* 2018, **9**(1):1-12.
- 712 28. Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, McInnes IB, Raza K, Young
713 SP: **Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with**
714 **rheumatoid arthritis.** *Arthritis & Rheumatism* 2013, **65**(6):1448-1456.
- 715 29. Cuppen BV, Fu J, Van Wietmarschen HA, Harms AC, Koval S, Marijnissen AC, Peeters JJ, Bijlsma JW,
716 Tekstra J, Van Laar JM: **Exploring the inflammatory metabolomic profile to predict response to**
717 **TNF- α inhibitors in rheumatoid arthritis.** *PloS one* 2016, **11**(9):e0163087.
- 718 30. Liebal UW, Phan AN, Sudhakar M, Raman K, Blank LM: **Machine Learning Applications for Mass**
719 **Spectrometry-Based Metabolomics.** *Metabolites* 2020, **10**(6):243.
- 720 31. Welsing PM, van Riel PL: **The Nijmegen inception cohort of early rheumatoid arthritis.** *The Journal*
721 *of Rheumatology Supplement* 2004, **69**:14-21.
- 722 32. Bates D, Mächler M, Bolker B, Walker S: **Fitting linear mixed-effects models using lme4.** *arXiv*
723 *preprint arXiv:14065823* 2014.
- 724 33. Siemons L, ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA: **How age and sex**
725 **affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis.**
726 *BMC musculoskeletal disorders* 2014, **15**(1):368.
- 727 34. Radovits B, Fransen J, Van Riel P, Laan R: **Influence of age and gender on the 28-joint Disease**
728 **Activity Score (DAS28) in rheumatoid arthritis.** *Annals of the rheumatic diseases* 2008, **67**(8):1127-
729 1131.
- 730 35. Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE: **Age adjustment corrects for**
731 **apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset**
732 **of seropositive rheumatoid arthritis in younger and older patients.** *The Journal of rheumatology*
733 2005, **32**(6):1040-1042.
- 734 36. Kuznetsova A, Brockhoff PB, Christensen RHB: **Package 'lmerTest'.** *R package version* 2015, **2**(0).

- 735 37. Yang XY, Di Zheng K, Lin K, Zheng G, Zou H, Wang JM, Lin YY, Chuka CM, Ge RS, Zhai W: **Energy**
736 **metabolism disorder as a contributing factor of rheumatoid arthritis: a comparative proteomic**
737 **and metabolomic study.** *PloS one* 2015, **10**(7).
- 738 38. Zhou J, Chan L, Zhou S: **Trigonelline: a plant alkaloid with therapeutic potential for diabetes and**
739 **central nervous system disease.** *Current medicinal chemistry* 2012, **19**(21):3523-3531.
- 740 39. Zhou J-Y, Du X-H, Zhang Z, Qian G-S: **Trigonelline inhibits inflammation and protects β cells to**
741 **prevent fetal growth restriction during pregnancy in a mouse model of diabetes.** *Pharmacology*
742 *2017*, **100**(5-6):209-217.
- 743 40. Foresti R, Green CJ, Motterlini R: **Generation of bile pigments by haem oxygenase: a refined cellular**
744 **strategy in response to stressful insults.** In: *Biochemical Society Symposia: 2004*: Portland Press
745 Limited; 2004: 177-192.
- 746 41. Bellner L, Vitto M, Patil KA, Dunn MW, Regan R, Laniado-Schwartzman M: **Exacerbated corneal**
747 **inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin.**
748 *Experimental eye research* 2008, **87**(3):268-278.
- 749 42. Nakao A, Otterbein LE, Overhaus M, Sarady JK, Tsung A, Kimizuka K, Nalesnik MA, Kaizu T,
750 Uchiyama T, Liu F: **Biliverdin protects the functional integrity of a transplanted syngeneic small**
751 **bowel.** *Gastroenterology* 2004, **127**(2):595-606.
- 752 43. Sarady-Andrews JK, Liu F, Gallo D, Nakao A, Overhaus M, Ollinger R, Choi AM, Otterbein LE:
753 **Biliverdin administration protects against endotoxin-induced acute lung injury in rats.** *American*
754 *Journal of Physiology-Lung Cellular and Molecular Physiology* 2005, **289**(6):L1131-L1137.
- 755 44. Gibbs PE, Maines MD: **Biliverdin inhibits activation of NF- κ B: Reversal of inhibition by human**
756 **biliverdin reductase.** *International journal of cancer* 2007, **121**(11):2567-2574.
- 757 45. Öllinger R, Wang H, Yamashita K, Wegiel B, Thomas M, Margreiter R, Bach FH: **Therapeutic**
758 **applications of bilirubin and biliverdin in transplantation.** *Antioxidants & redox signaling* 2007,
759 **9**(12):2175-2186.
- 760 46. Peng Y-F, Wang J-L, Pan G-G: **The correlation of serum bilirubin levels with disease activity in**
761 **patients with rheumatoid arthritis.** *Clinica Chimica Acta* 2017, **469**:187-190.
- 762 47. Fischman D, Valluri A, Gorrepati VS, Murphy ME, Peters I, Cheriya P: **Bilirubin as a protective**
763 **factor for rheumatoid arthritis: an NHANES study of 2003-2006 data.** *Journal of clinical medicine*
764 *research* 2010, **2**(6):256.
- 765 48. Jangi S, Otterbein L, Robson S: **The molecular basis for the immunomodulatory activities of**
766 **unconjugated bilirubin.** *The International Journal of Biochemistry & Cell Biology* 2013, **45**(12):2843-
767 2851.
- 768 49. Enot DP, Lin W, Beckmann M, Parker D, Overy DP, Draper J: **Preprocessing, classification modeling**
769 **and feature selection using flow injection electrospray mass spectrometry metabolite fingerprint**
770 **data.** *Nature Protocols* 2008, **3**(3):446-470.
- 771 50. Grissa D, Pétéra M, Brandolini M, Napoli A, Comte B, Pujos-Guillot E: **Feature selection methods for**
772 **early predictive biomarker discovery using untargeted metabolomic data.** *Frontiers in molecular*
773 *biosciences* 2016, **3**:30.
- 774 51. van Zanten JV, Ring C, Carroll D, Kitas GD: **Increased C reactive protein in response to acute stress**
775 **in patients with rheumatoid arthritis.** *Annals of the rheumatic diseases* 2005, **64**(9):1299-1304.
- 776 52. Graf J, Scherzer R, Grunfeld C, Imboden J: **Levels of C-reactive protein associated with high and**
777 **very high cardiovascular risk are prevalent in patients with rheumatoid arthritis.** *PLoS One* 2009,
778 **4**(7):e6242.
- 779 53. Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, Kitas GD, Raza K: **The impact of**
780 **inflammation on metabolomic profiles in patients with arthritis.** *Arthritis & Rheumatism* 2013,
781 **65**(8):2015-2023.
- 782 54. Wells G, Becker J, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, Van Riel P: **Validation of the**
783 **28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response**
784 **criteria based on C-reactive protein against disease progression in patients with rheumatoid**

- 785 **arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.** *Annals of the*
786 *rheumatic diseases* 2009, **68**(6):954-960.
- 787 55. Patel CH, Leone RD, Horton MR, Powell JD: **Targeting metabolism to regulate immune responses**
788 **in autoimmunity and cancer.** *Nature Reviews Drug Discovery* 2019, **18**(9):669-688.
- 789 56. Bettencourt IA, Powell JD: **Targeting metabolism as a novel therapeutic approach to autoimmunity,**
790 **inflammation, and transplantation.** *The Journal of Immunology* 2017, **198**(3):999-1005.
- 791 57. Spies CM, Straub RH, Buttgerit F: **Energy metabolism and rheumatic diseases: from cell to**
792 **organism.** *Arthritis research & therapy* 2012, **14**(3):216.
- 793 58. Yang Z, Matteson EL, Goronzy JJ, Weyand CM: **T-cell metabolism in autoimmune disease.** *Arthritis*
794 *research & therapy* 2015, **17**(1):29.
- 795 59. Fearon U, Hanlon M, Wade S, Fletcher J: **Altered metabolic pathways regulate synovial inflammation**
796 **in rheumatoid arthritis.** *Clinical & Experimental Immunology* 2019, **197**(2):170-180.
- 797 60. Chimenti M, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R: **The interplay between**
798 **inflammation and metabolism in rheumatoid arthritis.** *Cell death & disease* 2015, **6**(9):e1887-e1887.
- 799 61. Sanchez-Lopez E, Cheng A, Guma M: **Can metabolic pathways be therapeutic targets in rheumatoid**
800 **arthritis?** *Journal of clinical medicine* 2019, **8**(5):753.
- 801 62. Sung J, Wang Y, Chandrasekaran S, Witten DM, Price ND: **Molecular signatures from omics data:**
802 **from chaos to consensus.** *Biotechnology journal* 2012, **7**(8):946-957.
- 803 63. Coras R, D Murillo-Saich J, Guma M: **Circulating Pro-and Anti-Inflammatory Metabolites and Its**
804 **Potential Role in Rheumatoid Arthritis Pathogenesis.** *Cells* 2020, **9**(4):827.
- 805 64. Wegiel B, Otterbein L: **Go green: the anti-inflammatory effects of biliverdin reductase.** *Frontiers in*
806 *pharmacology* 2012, **3**:47.
- 807 65. Wegiel B, Gallo D, Csizmadia E, Roger T, Kaczmarek E, Harris C, Zuckerbraun BS, Otterbein LE:
808 **Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear**
809 **translocation of biliverdin reductase.** *Proceedings of the National Academy of Sciences* 2011,
810 **108**(46):18849-18854.
- 811 66. Vogel ME, Zucker SD: **Bilirubin acts as an endogenous regulator of inflammation by disrupting**
812 **adhesion molecule-mediated leukocyte migration.** *Inflammation and cell signaling* 2016, **3**(1).
- 813 67. Liu Y, Li P, Lu J, Xiong W, Oger J, Tetzlaff W, Cynader M: **Bilirubin possesses powerful**
814 **immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis.** *The*
815 *Journal of Immunology* 2008, **181**(3):1887-1897.
- 816 68. Tang W, Wu Y, Wu B: **Heme catabolic pathway in inflammation and immune disorders.** *Frontiers*
817 *in pharmacology* 2019, **10**:825.
- 818 69. Öllinger R, Yamashita K, Bilban M, Erat A, Kogler P, Thomas M, Csizmadia E, Usheva A, Margreiter
819 R, Bach FH: **Bilirubin and biliverdin treatment of atherosclerotic diseases.** *Cell Cycle* 2007, **6**(1):39-
820 43.
- 821 70. Pellock SJ, Redinbo MR: **Glucuronides in the gut: Sugar-driven symbioses between microbe and**
822 **host.** *Journal of Biological Chemistry* 2017, **292**(21):8569-8576.
- 823 71. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T: **Involvement**
824 **of β -glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin**
825 **derivative irinotecan hydrochloride (CPT-11) in rats.** *Cancer research* 1996, **56**(16):3752-3757.
- 826 72. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA: **Pharmacologic targeting of**
827 **bacterial β -glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in**
828 **mice.** *Journal of Pharmacology and Experimental Therapeutics* 2012, **341**(2):447-454.
- 829 73. Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Nelson H, Matteson EL, Taneja V: **An**
830 **expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.** *Genome medicine*
831 2016, **8**(1):1-14.
- 832 74. He M, Harms AC, van Wijk E, Wang M, Berger R, Koval S, Hankemeier T, van der Greef J: **Role of**
833 **amino acids in rheumatoid arthritis studied by metabolomics.** *International Journal of Rheumatic*
834 *Diseases* 2019, **22**(1):38-46.

- 835 75. Tilwawala R, Nguyen SH, Maurais AJ, Nemmara VV, Nagar M, Salinger AJ, Nagpal S, Weerapana E,
836 Thompson PR: **The rheumatoid arthritis-associated citrullinome.** *Cell chemical biology* 2018,
837 **25(6):691-704.** e696.
- 838 76. Marietta EV, Murray JA, Luckey DH, Jeraldo PR, Lamba A, Patel R, Luthra HS, Mangalam A, Taneja
839 V: **Suppression of inflammatory arthritis by human gut-derived *Prevotella histicola* in humanized**
840 **mice.** *Arthritis & rheumatology* 2016, **68(12):2878-2888.**
- 841 77. Liu X, Zou Q, Zeng B, Fang Y, Wei H: **Analysis of fecal *Lactobacillus* community structure in**
842 **patients with early rheumatoid arthritis.** *Current microbiology* 2013, **67(2):170-176.**
- 843 78. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y: **The oral and gut**
844 **microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment.** *Nature*
845 *medicine* 2015, **21(8):895-905.**
- 846 79. Sung J, Kim S, Cabatbat JJT, Jang S, Jin Y-S, Jung GY, Chia N, Kim P-J: **Global metabolic interaction**
847 **network of the human gut microbiota for context-specific community-scale analysis.** *Nature*
848 *communications* 2017, **8(1):1-12.**
- 849 80. Wilmanski T, Rappaport N, Earls JC, Magis AT, Manor O, Lovejoy J, Omenn GS, Hood L, Gibbons SM,
850 Price ND: **Blood metabolome predicts gut microbiome α -diversity in humans.** *Nature biotechnology*
851 2019, **37(10):1217-1228.**
- 852 81. Gupta VK, Kim M, Bakshi U, Cunningham KY, Davis JM, Lazaridis KN, Nelson H, Chia N, Sung J: **A**
853 **predictive index for health status using species-level gut microbiome profiling.** *Nature*
854 *communications* 2020, **11(1):1-16.**

855